Gould Robert J

SEC source: 0001193125-26-294697 · ownership.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2036-06-29

F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001193125-26-037573 · ownership.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 454,864

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001193125-26-004572 · ownership.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 469,864

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001193125-26-037606 · ownership.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 469,864

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726.

SEC source: 0001193125-25-291392 · ownership.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,864

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000950170-25-091578 · ownership.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2035-06-25

F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000950170-24-074888 · ownership.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-16

F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0001415889-24-018926 · form4-07022024_040708.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,770

Underlying: Common Stock · 12,770 shares

Expires 2034-06-02

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0000950170-23-030753 · ownership.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director · Interim President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-26

F1 · derivative.exercise_date: This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-23-001803 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 499,864

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.

SEC source: 0000899243-22-024527 · doc4.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2032-06-26

F1 · derivative.exercise_date: This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-22-021530 · doc4.xml · derivative · entry 3

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,523

Underlying: Common Stock · 71,435 shares

Expires 2022-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F3 · derivative.exercise_date: This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.

SEC source: 0000899243-22-021530 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.35, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-22-021530 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-021250 · doc4.xml · derivative · entry 9

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,958

Underlying: Common Stock · 24,382 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 6

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.59, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 5

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 531,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-021250 · doc4.xml · derivative · entry 8

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,340

Underlying: Common Stock · 25,551 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 4

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 3

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 532,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-021250 · doc4.xml · derivative · entry 7

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,891

Underlying: Common Stock · 16,689 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-22-021250 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523,319

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-014438 · doc4.xml · derivative · entry 3

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,580

Underlying: Common Stock · 5,631 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F3 · derivative.exercise_date: This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-22-014438 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.09, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-22-014438 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 512,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-013881 · doc4.xml · derivative · entry 9

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,211

Underlying: Common Stock · 52,552 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 6

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 5

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 559,182

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-013881 · doc4.xml · derivative · entry 8

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,763

Underlying: Common Stock · 7,235 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 4

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 3

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 513,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-22-013881 · doc4.xml · derivative · entry 7

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,998

Underlying: Common Stock · 34,464 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F5 · derivative.exercise_date: This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.17, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-22-013881 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 541,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.

SEC source: 0000899243-21-012179 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-21-012179 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,419

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.51, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-21-007119 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 516,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.88, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-21-007119 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 518,303

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.48 to $14.47, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-21-004949 · doc4.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,390

Underlying: Common Stock · 269,390 shares

Expires 2031-02-01

F1 · derivative.exercise_date: This option was granted on February 2, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service.

SEC source: 0000899243-21-002928 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 524,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.365, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-018815 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

SEC source: 0000899243-20-017758 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 537,345

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $21.26, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-015959 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 539,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

SEC source: 0000899243-20-015784 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 540,001

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-015437 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 543,434

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-20-015437 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,734

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-015063 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 546,234

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

SEC source: 0000899243-20-015063 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,031

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

SEC source: 0000899243-20-014721 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,036

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.22, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.